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The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus, SARS-associated
coronavirus (SARS-CoV). CD8 T cells play an important role in controlling diseases caused by other coronaviruses and in mediating
vaccine-induced protective immunity in corresponding animal models. The spike protein, a main surface antigen of SARS-CoV, is one of
the most important antigen candidates for vaccine design. Overlapping peptides were used to identify major histocompatibility complex
class I-restricted epitopes in mice immunized with vectors encoding codon-optimized SARS-CoV spike protein. CD8 T-cell responses were
mapped to two H-2b-restricted epitopes (S436–443 and S525–532) and one H-2d-restricted epitope (S366–374). The identification of
these epitopes will facilitate the evaluation of vaccine strategies in murine models of SARS-CoV infection. Furthermore, codon and
promoter optimizations can greatly enhance the overall immunogenicity of spike protein in the context of replication-defective human and
simian adenoviral vaccine carriers. The optimized recombinant adenoviral vaccine vectors encoding spike can generate robust antigen-
specific cellular immunity in mice and may potentially be useful for control of SARS-CoV infection.
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Severe acute respiratory syndrome (SARS) is an emerg-
ing infectious disease associated with a novel coronavirus,
SARS-associated coronavirus (SARS-CoV), which caused
worldwide outbreaks. The case fatality rate has been as high
as 15% for patients younger than 60 years old and can be
higher than 50% for patients 60 years or older. Nearly 40%
of patients developed respiratory failure that required
assisted ventilation (De Groot, 2003). The severe morbidity
and mortality associated with SARS make it imperative that
effective means to prevent and treat the disease be0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: wilsonjm@mail.med.upenn.edu (J.M. Wilson).developed and evaluated, especially since it is not known
whether the virus will exhibit a seasonal pattern or whether
it will be reintroduced into the human population through
animal reservoirs, or laboratory accidences, or acts of
terrorism.
The successful development of effective treatments and
vaccines against SARS-CoV depends on understanding the
roles of various immune effectors in protective immunity
and identifying protective antigens recognized by these
effector cells. Like other CoVs, SARS-CoV is an enveloped
plus-stranded RNA virus with a ¨30 kbs genome encoding
replicase (Rep) gene products and the structural proteins
spike (S), envelope (E), membrane (M), and nucleocapsid
(N) (Marra et al., 2003; Rota et al., 2003). S protein is
responsible for binding to specific cellular receptor (Li et al.,
2003), E protein plays a role in viral assembly, M is005) 34 – 45
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with viral RNA packaging (Holmes, 2003). No conclusive
information is available on the immune correlates of
protection to SARS in patients. However, it has been
reported that antibodies against SARS-CoV were detected in
patients infected with SARS (Ksiazek et al., 2003).
Recently, using pseudotyped lentiviral particles bearing
the SARS-CoV spike protein, it has been shown that
spike-mediated infection could be inhibited by sera from
SARS patients, demonstrating that spike is a target for
neutralizing antibodies (Hofmann et al., 2004). In addition,
two identified CD8 T-cell epitopes in SARS-CoV spike
protein have been shown to elicit specific T-cell responses in
HLA-A2+ SARS-CoV-infected patients (Wang et al., 2004).
Therefore, we initially focused on SARS-CoV spike protein
as the target antigen for our vaccine development.
A number of animal models have emerged for studying
SARS pathogenesis and evaluating therapies including
macaques, ferrets, and mice (Fouchier et al., 2003; Hogan
et al., 2004; Kuiken et al., 2003; Martina et al., 2003;
Subbarao et al., 2004). However, for the early stage of
product evaluation, a small animal model, such as mice,
would be very useful. We (Hogan et al., 2004) and others
(Subbarao et al., 2004) have shown that SARS-CoV
replicates in mice although the infection is self-limited. To
study antigen-specific immune responses in mice, MHC I-
restricted CD8 T-cell epitopes need to be identified. Vectors
based on replication-defective adenoviruses are capable of
high-level gene transfer and activation of T and B cells to the
transgene product (van Ginkel et al., 1997; Yang et al.,
1996). These properties have been exploited in the develop-
ment of genetic subunit vaccines (Sullivan et al., 2000;
Xiang et al., 1996). Therefore, several versions of replica-
tion-defective adenoviral vectors expressing spike protein
were created to induce spike-specific T cell responses in mice
and to screen for CD8 T-cell epitopes using an overlapping
peptide library spanning the entire spike protein in IFN-g
ELISPOT and intracellular IFN-g staining assays. Here, we
report the detailed mapping of both H-2b- and H-2d-restricted
CD8 T-cell epitopes from codon-optimized spike protein.
These results provide critical information for analyzing CD8
T-cell responses in murine models of SARS-CoV infection
and for developing spike-based SARS-CoV vaccines. More
importantly, a single administration of the optimized SARS-
CoV spike vaccine vectors based on replication-defective
human and simian adenovirus can generate strong spike-
specific CD8 T-cell responses in mice.Results
Mapping of H-2b-restricted CD8 T-cell epitopes in
SARS-CoV spike protein
To identify CD8 T-cell epitopes in SARS-CoV spike
protein, C57BL/6 mice were injected im with AdHu5.CMVSpike, a replication-defective human adenovirus
serotype 5-based vaccine vector encoding wild-type spike
protein. Splenocytes were harvested 8 days after immuni-
zation and stimulated in vitro with pools of overlapping
peptides corresponding to spike protein. No pool resulted in
specific stimulation of an IFN-g response in T cells using
ELISPOT assay (data not shown).
We then used AdHu5.CMVnSpike, another replication-
defective human adenovirus serotype 5-based vaccine
vector encoding codon-optimized spike protein, to immu-
nize C57BL/6 mice im. Splenocytes were harvested at 8
days after immunization and subjected to IFN-g ELISPOT
assay with pools of overlapping peptides from spike
protein. Of all peptide pools screened, pools 9, 11, and 18
showed specific IFN-g responses in C57BL/6. The remain-
ing pools, as exemplified by pool 5, showed no specific
response (Fig. 1A). Pools 9 and 11 were selected for
mapping the individual peptide(s) responsible for stimulat-
ing IFN-g expressing T cells. Peptide 87 (TSTGNYNY-
KYRYLRH, corresponding to S431–445) and peptide 88
(YNYKYRYLRHGKLRP, corresponding to S436–450)
within pool 9 and peptide 105 (KNQCVNFNFNGLTGT,
corresponding to S521–535) and peptide 106 (NFNFN-
GLTGTGVLTP, corresponding to S526–540) within pool
11 were identified as the major positive peptides respon-
sible for specific stimulation of T cells to produce IFN-g
(Fig. 1B). Based on the SYFPEITHI algorithm (Rammen-
see et al., 1999), several potential CD8 T-cell epitopes for
SARS-CoV spike protein in C57BL/6 mice were identified.
Table 1 showed their sequences, positions, and scores.
Indeed, YNYKYRYL (S436–443) completely present in
peptides 87 and 88 was predicted to have strong binding
affinity for H2-Kb; while VNFNFNGL (S525–532) com-
pletely present in peptide 105 and partially present in
peptide 106 was predicted to have weak binding affinity
for H2-Kb. Since ELISPOT assay cannot readily distin-
guish antigen-specific CD4 T-cell responses from antigen-
specific CD8 T-cell responses, the immunized splenocytes
were further subjected to intracellular IFN-g staining after
stimulating in vitro with peptides 87 and 105 (Fig. 2).
Subsequently, the predicted optimal CD8 T-cell epitopes,
YNYKYRYL resided in peptide 87 and VNFNFNGL
resided in peptide 105, were synthesized and used to
stimulate immunized splenocytes in vitro for IFN-g
secretion (Fig. 2). As predicted, YNYKYRYL and peptides
87 gave much stronger CD8 T-cell responses than
VNFNFNGL and peptides 105. Furthermore, optimal
epitopes, YNYKYRYL and VNFNFNGL, were able to
induce IFN-g responses in CD8 T cells either as effectively
as or more effectively than their parental 15 mers,
respectively. In conclusion, a single administration of a
replication-defective human adenoviral vaccine vector
encoding codon-optimized spike can generate strong
spike-specific CD8 T-cell responses. We also identified
two optimal CD8 T-cell epitopes of SARS-CoV spike in
C57BL/6 mice.
Fig. 1. IFN-g ELISPOT assay to map T cell epitopes of SARS-CoV spike protein in C57BL6 mice. Mice were immunized with 5  1010 particles of
AdHu5.CMVnSpike via im injection. 8 days after immunization, splenocytes were harvested and pooled from 5 mice and stimulated in vitro with either pools
of overlapping peptides from spike protein (A) or individual peptides from positive pools (B) for IFN-g ELISPOT assay. Experiments were done in duplicate
and representative results were shown.
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T-cell epitopes for T cell activation
Immunized C57BL/6 splenocytes were in vitro stimu-
lated with the two identified optimal CD8 T-cell epitopes at
different concentrations ranging from 5 Ag/ml to 5e7 Ag/
ml, respectively. T cells activation was measured by
intracellular IFN-g staining (Fig. 3). It appeared that the
minimal amounts of peptides needed to fully activate T cells
in vitro were similar for both epitopes, even though the
magnitude of T cell response with YNYKYRYL was much
higher than that with VNFNFNGL.
Mapping of H-2d-restricted CD8 T-cell epitopes in
SARS-CoV spike protein
BALB/c mice were immunized in a similar fashion as
C57BL/6 mice. Using ELISPOT assay, pools 7, 8, and 9
showed specific IFN-g responses in BALB/c. The remain-
ing pools, as exemplified by pool 5, showed no specific
response (Fig. 4A). We focused on pools 8 and 9 because of
the stronger responses observed with these pools. Sub-
sequently, peptide 73 (FSTFKCYGVSATKLN, correspond-Table 1
Selected candidates of CD8 T-cell epitopes for SARS-CoV spike protein in C57B
The candidates of CD8 T-cell epitopes present in the positive 15 mers were showing to S361–375) and peptide 74 (CYGVSATKLNDLCFS,
corresponding to S366–380) within pool 8 and peptide 87
(TSTGNYNYKYRYLRH, corresponding to S431–445)
and peptide 88 (YNYKYRYLRHGKLRP, corresponding
to S436–450) within pool 9 were identified as the major
positive peptides responsible for specific stimulation of T
cells to produce IFN-g (Fig. 4B). Based on the SYFPEITHI
algorithm (Rammensee et al., 1999), several potential CD8
T-cell epitopes for SARS-CoV spike protein in BALB/c
mice were identified. Table 2 showed their sequences,
positions, and scores. Indeed, CYGVSATKL (S366–374)
completely present in peptides 73 and 74 was predicted to
have strong binding affinity for H2-Kd; while NYNY-
KYRYL (S435–443) completely present in peptide 87 and
partially present in peptide 88 was predicted to have weak
binding affinity for H2-Kd. The immunized splenocytes
were also subjected to intracellular IFN-g staining after
stimulating in vitro with these positive 15 mers. Notably,
there was no significant IFN-g production from CD8 T cells
stimulated with peptides 87 and 88 by intracellular IFN-g
staining (Fig. 5A), even though both peptides gave strong
responses in IFN-g ELISPOT assay (Fig. 4B). This
suggested that peptides 87 and 88 may contain a CD4 T-L/6
n in red.
Fig. 2. Intracellular IFN-g staining to confirm CD8 T-cell epitopes of SARS-CoV spike protein in C57BL/6 mice. Mice were immunized with 3  1010
particles of AdHu5.CMVnSpike via im injection. 10 days after immunization, splenocytes were harvested and pooled from 3 mice and stimulated with either
15 mers positive peptides or optimal 8 mers CD8 T-cell epitopes, as indicated, for 5 h. The immune response was evaluated by intracellular IFN-g staining with
PE-anti-IFN-g and FITC-anti-CD8 antibodies. Numbers in the upper right corner of each graph represent the frequencies of IFN-g-producing CD8 T cells.
Experiments were done in duplicate and representative results were shown.
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ELISPOT assay. In contrast, peptide 74 can significantly
stimulate CD8 T-cell responses (Fig. 5B). Subsequently, the
predicted optimal CD8 T-cell epitope, CYGVSATKL
resided in peptide 74, was synthesized and used to stimulate
immunized splenocytes in vitro for IFN-g secretion (Fig.Fig. 3. Dose responses of H-2b-restricted CD8 T-cell epitopes for T cell activa
AdHu5.CMVnSpike via im injection. 8 days after immunization, splenocytes were
T-cell epitopes at different concentrations, as indicated, respectively, for 5 h. T cell
done in duplicate and representative results were shown.5B). The results indicated that peptide 74 indeed contained
an H-2d-restricted CD8 T-cell epitope. As expected, optimal
epitope was able to induce IFN-g responses in CD8 T cells
more effectively than its parental 15 mer. Collectively, we
have identified one optimal CD8 T-cell epitope of SARS-
CoV spike in BALB/c mice. The dose responses of thistion in vitro. C57BL/6 mice were immunized with 5  1010 particles of
harvested and pooled from 3 mice and stimulated with two identified CD8
activation was evaluated by intracellular IFN-g staining. Experiments were
Fig. 4. IFN-g ELISPOT assay to map T cell epitopes of SARS-CoV spike protein in BALB/c mice. Mice were immunized with 5  1010 particles of
AdHu5.CMVnSpike via im injection. 8 days after immunization, splenocytes were harvested and pooled from 5 mice and stimulated in vitro with either pools
of overlapping peptides from spike protein (A) or individual peptides from positive pools (B) for IFN-g ELISPOT assay. Experiments were done in duplicate
and representative results were shown.
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determined as described above (Fig. 6). The results
suggested that about 100-fold more peptides were needed
to fully activate T cells in vitro with this H-2d-restricted
CD8 T-cell epitope compared to those with two H-2b-
restricted CD8 T-cell epitopes (Fig. 3). Furthermore,
peptides 87 and 88 may contain a CD4 T-cell epitope of
SARS-CoV spike in BALB/c mice.
Identifying the potential CD4 T-cell epitope(s) of SARS-CoV
spike protein in BALB/c
To confirm the presence of CD4 T-cell epitope(s) in
peptides 87 and 88, the AdHu5.CMVnSpike-immunized
splenocytes of BALB/c mice were harvested and in vitro
stimulated with three 15 mers individually, including
peptides 74, 87, and 88. The CD4 T-cell response was
directly evaluated by intracellular cytokine staining with
FITC-anti-CD4 and PE-anti-IFN-g antibodies (Fig. 7). As
expected, when stimulated with peptide 74, there was no
detectable IFN-g secretion from immunized CD4 T cells,
even though a significant IFN-g production from immu-
nized non-CD4 T cells (CD8 T cells) was observed. More
importantly, peptides 87 and 88 were able to stimulateTable 2
Selected candidates of CD8 T-cell epitopes for SARS-CoV spike protein in BAL
The candidates of CD8 T-cell epitopes present in the positive 15 mers were showimmunized CD4 T cells to product IFN-g. These results
indicated that peptides 87 and 88 indeed contained a CD4
T-cell epitope of spike protein in BALB/c mice.
Increasing the immunogenicity of SARS-CoV spike protein
in the context of replication-defective simian adenoviral
vaccine carrier
To circumvent the potential problem that neutralizing
antibodies to human adenovirus serotype 5 vector by
previous natural infections will impair its efficacy as vaccine
carrier, our lab recently developed a series of novel
replication-defective adenoviral vaccine carriers based on
simian serotypes (Fitzgerald et al., 2003; Pinto et al., 2003).
AdC7, one of those carriers, is able to induce robust
transgene-specific CD8 T-cell responses in immunized mice
(Kobinger et al., submitted for publication). Three repli-
cation-defective simian adenovirus serotype 7-based vac-
cine vectors encoding either wild-type spike driven by CMV
promoter (AdC7.CMVSpike) or codon-optimized spike
driven by CMV promoter (AdC7.CMVnSpike) or codon-
optimized spike driven by a hybrid promoter CAG2
(AdC7.CAG2nSpike) were created and used to immunize
mice. CAG2 promoter was created by deleting a 955-bpB/c
n in red.
Fig. 5. Intracellular IFN-g staining to confirm CD8 T-cell epitopes of SARS-CoV spike protein in BALB/c mice. Mice were immunized with 3  1010 particles
of AdHu5.CMVnSpike via im injection. 10 days after immunization, splenocytes were harvested and pooled from 3 mice and stimulated with either 15 mers
positive peptides or optimal 8 mers CD8 T-cell epitope, as indicated, for 5 h. The immune response was evaluated by intracellular IFN-g staining with PE-anti-
IFN-g and FITC-anti-CD8 antibodies. Numbers in the upper right corner of each graph represent the frequencies of IFN-g-producing CD8 T cells. Experiments
were done in duplicate and representative results were shown.
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(Niwa et al., 1991). Similar to the negative results observed
when AdHu5.CMVSpike was used to immunize mice, there
was no detectable stimulation of an IFN-g response in T
cells with any of the identified positive pools using
ELISPOT assay when AdC7.CMVSpike was used for
immunization (data not shown). In contrast, spike-specific
CD8 T-cell responses were observed when AdC7.CMVnS-
pike vector was used to immunize C57BL/6 mice (Fig. 8).
However, the magnitude of spike-specific CD8 T-cellFig. 6. Dose responses of H-2d-restricted CD8 T-cell epitope for T cell activa
AdHu5.CMVnSpike via im injection. 8 days after immunization, splenocytes were
cell epitope at different concentrations, as indicated, for 5 h. T cell activation was e
and representative results were shown.responses was much lower than that observed in mice
immunized with AdHu5.CMVnSpike vector (Fig. 8). In
order to further improve the immunogenicity of spike
protein delivered by the simian adenoviral vaccine carrier,
AdC7.CAG2nSpike vector was created. Chicken h-actin
promoter has been shown to increase expression of SARS-
CoV spike protein in transfected cells (Simmons et al.,
2004). Spike-specific CD8 T-cell responses in C57BL/6
mice elicited by AdC7.CAG2nSpike vector were examined
by intracellular IFN-g staining (Fig. 8). The result indicatedtion in vitro. BALB/c mice were immunized with 5  1010 particles of
harvested and pooled from 3 mice and stimulated with the identified CD8 T-
valuated by intracellular IFN-g staining. Experiments were done in duplicate
Fig. 7. Intracellular IFN-g staining to confirm the presence of CD4 T-cell
epitope of SARS-CoV spike protein in BALB/c mice. Mice were
immunized with 5  1010 particles of AdHu5.CMVnSpike via im injection.
10 days after immunization, splenocytes were harvested and pooled from 3
mice and stimulated with 15 mers, as indicated, for 5 h. The immune
response was evaluated by intracellular IFN-g staining with PE-anti-IFN-g
and FITC-anti-CD4 antibodies. Numbers in the upper right corner of each
graph represent the frequencies of IFN-g-producing CD4 T cells. Experi-
ments were done in duplicate and representative results were shown.
Y. Zhi et al. / Virology 335 (2005) 34–4540that codon and promoter optimizations can greatly enhance
the overall immunogenicity of SARS-CoV spike protein in
the context of simian adenoviral vaccine carrier. More
importantly, a single administration of an optimized SARS-
CoV spike vaccine vector based on a replication-defective
simian adenovirus can generate strong spike-specific CD8
T-cell responses in mice.
Correlating the immunogenicity of SARS-CoV spike protein
to its expression
It has been shown that increased expression of codon-
optimized HIV gag protein is responsible for its enhanced
immunogenicity in mice (Deml et al., 2001; Gao et al.,
2003a). Therefore, it was of interest to determine whether
optimization of transgene expression cassette, including
codon and promoter optimizations, in the context of
replication-deficient adenoviral vaccine vectors also resulted
in the increased expression of spike protein in vitro.
Expression of spike protein in Ad vector-infected 293T
cells was examined by Western blot analysis and the bands
representing spike protein were quantified by Image-
Quant5.1. Forty-three-fold increase of protein expression
was achieved when CAG2 promoter, instead of CMV
promoter, was used in the simian adenoviral C7 vector (Fig.9, lanes 4 and 6), while 7-fold increase of protein expression
was achieved when codon optimization of spike protein was
applied (Fig. 9, lanes 5 and 6). Overall, the results supported
that the enhanced immunogenicity of spike in mice injected
with AdHu5.CMVnSpike and AdC7.CAG2nSpike vaccine
vectors (Fig. 8) indeed correlated to high expression of spike
protein in cells infected with these vectors.Discussion
SARS-CoV represents an emerging threat. Currently, no
effective therapies or vaccines exist, and relatively little is
known about the pathogenesis of the virus. It has been
shown that 293T cells transfected with a functional receptor
for SARS-CoV, angiotensin-converting enzyme 2 (ACE2),
formed multinucleated syncytia with cells expressing spike
protein (Li et al., 2003). More significantly, in the post-
mortem lung tissue samples from patients who died from
SARS, multinucleate giant cells of macrophage and
epithelial origins have been observed within the damaged
alveoli (Nicholls et al., 2003). In addition, CD8 T-cell
responses are necessary for clearance of other CoVs, such as
mouse hepatitis virus (Sussman et al., 1989; Williamson and
Stohlman, 1990). Therefore, eradication of SARS-CoV may
not be achieved by humoral response alone and T cell-
mediated immunity may be also required to clear infection.
To study more closely cellular immune responses in murine
model, MHC I-restricted CD8 T-cell epitopes need to be
identified. In this study, we have identified two octamers
(S436–443 and S525–532) as H-2b-restricted CD8 T-cell
epitopes and one nonamer (S366–374) as an H-2d-restricted
CD8 T-cell epitope. In C57BL/6 mice, one epitope is more
dominant than the other in immunized mice. The strength of
these epitopes appeared to correlate with the binding affinity
to H2-Kb predicted by SYFPEITHI algorithm. In the
preliminary study, splenocytes were collected from
C57BL/6 mice immunized with AdC7.CAG2nSpike vector
and in vitro cultured in the presence of the dominant H-2b-
restricted CD8 T-cell epitope for a week. Subsequently, the
cultured splenocytes were subjected to ELISPOT assay
stimulated with MC57SV cells (H-2Db, a cell line derived
from B6 mice) previously infected with either AdHu5.Null
or AdHu5.CMVnSpike vector. The initial results indicated
that cultured splenocytes were able to induce higher level of
IFN-g response after stimulated with AdHu5.CMVnSpike
vector-infected MC57SV cells than after stimulated with
AdHu5.Null vector-infected MC57SV cells. These data
suggested that T cells raised to the epitope were able to
recognize cells expressing the spike protein and that the
identified CD8 epitope is naturally processed and presented
by cells. Currently, additional experiments are underway to
address this issue more thoroughly.
Coronaviruses are common and worldwide pathogens
that infect a variety of mammals and birds. These viruses
have been classified into three groups. Although SARS-
Fig. 8. Promoter optimization can further increase the immunogenicity of SARS-CoV spike protein delivered by the replication-defective simian adenoviral
vaccine carrier. C57BL/6 mice were immunized with 5  1010 particles of vaccine vectors, including AdHu5.CMVnSpike, AdC7.CMVnSpike, and
AdC7.CAG2nSpike, via im injection. 10 days after immunization, splenocytes were harvested and pooled from 3 mice in each group and stimulated in vitro
with positive peptide for 5 h. The immune response was evaluated by intracellular IFN-g staining with PE-anti-IFN-g and FITC-anti-CD8 antibodies. Numbers
in the upper right corner of each graph represent the frequencies of IFN-g-producing CD8 T cells. Experiments were done in duplicate and representative
results were shown.
Fig. 9. Expression of SARS-CoV spike protein from a panel of replication-defective adenoviral vaccine vectors encoding spike in vitro. 293T cells were
infected with each recombinant adenoviral vector encoding spike, as indicated. Infected cell lysates were made and separated by SDS–PAGE. Expression of
spike protein was detected by Western blot using the whole serum collected from rabbits inoculated with purified spike protein. Uninfected cell lysate served as
negative control and supernatant made from SARS-CoV-infected Vero cells served as positive control. Molecular weight markers were shown. The expected
spike protein band was indicated by arrow.
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related to known CoVs and Fmost like_ Group 2 CoVs,
which includes bovine, murine, and human viruses (Snijder
et al., 2003). The most commonly studied coronavirus is
mouse hepatitis virus (MHV), in part because the natural
host for this infection, the mouse, is more easily managed
in the laboratory. Two spike-specific CD8 T-cell epitopes
(dominant S510–518 and subdominant S598–605) were
identified in MHV-infected C57BL/6 mice (Bergmann et
al., 1996; Castro and Perlman, 1995), while no spike-
specific CD8 T-cell epitope has been recognized in MHV-
infected BALB/c mice. The dominant S510–518 epitope is
located in a hypervariable region of spike protein that
appears to be readily deleted without loss of viability of
MHV (Parker et al., 1989). In contrast, it was impossible to
recover infectious virus with mutations in the subdominant
S598–605 epitope (personal communication, M.M. Chua
and S.R. Weiss). Examination of SARS-CoV spike
sequence reveals that three CD8 T-cell epitopes are present
in the S1 domain of the spike protein. Specifically, the
dominant CD8 T-cell epitope in C57BL/6 (S436–443) and
the CD8 T-cell epitope in BALB/c (S366–374) both reside
in the minimal region of S1 required for interaction with its
cellular receptor (Babcock et al., 2004; Wong et al., 2004).
Several spike-specific CD4 T-cell epitopes have also been
reported in MHV-infected mice (Heemskerk et al., 1995;
Xue and Perlman, 1997). CD4 T cells are needed to help
CD8 cells for viral clearance (Stohlman et al., 1998;
Sussman et al., 1989; Williamson and Stohlman, 1990). In
this study, we clearly showed that both peptide 87 and
peptide 88 were able to specifically stimulate immunized
CD4 T cells to produce IFN-g in vitro. However, the exact
sequences of CD4 T-cell epitope in the 431–450 region of
spike protein remain to be further elucidated.
The first step in designing a genetic vaccine is to enhance
the intrinsic immunogenicity of the selected target gene. In
this study, we demonstrated that codon and promoter
optimizations can greatly enhance the overall immunoge-
nicity of spike protein in replication-defective human and
simian adenoviral vaccine vectors. We showed that the
expression of spike protein in vitro was greatly increased by
expression cassette optimization. This provided useful
information for developing spike-based SARS-CoV genetic
vaccines. More importantly, this may provide us a platform
to quickly generate genetic vaccine vectors based on simian
adenovirus. Namely, CAG2 but not CMV promoter should
be used in simian adenoviral vaccine vector. Currently, we
are testing this hypothesis with other viral antigens. Since
the CMV promoter has been widely used in human
adenoviral vectors, it is surprising to see the inferior
performance of CMV promoter in simian adenoviral vector.
One possibility is that certain viral sequences only present in
simian adenoviral vector have negative effects on CMV
promoter activity. The other possibility is that certain
inflammatory cytokines induced by simian adenoviral
vector may inhibit CMV promoter activity.Recently, a strategy involving priming with DNAvaccine
and boosting with adenoviral vaccine vectors, each express-
ing a similar antigen, has resulted in the generation of
unparalleled levels of specific immunity and afforded
protection against infectious agents in animal models
(Shiver et al., 2002; Sullivan et al., 2000). Nevertheless,
DNA vaccines have performed poorly in clinical trials so far
(MacGregor et al., 1998; Wang et al., 2001), and it is thus
uncertain whether DNA vaccine prime followed by adeno-
viral vaccine vector boost will be as efficacious in humans
as in preclinical experimental animal studies. Therefore, we
developed an additional replication-defective adenoviral
vaccine vector of chimpanzee origin to increase our
repertoire of vaccine carriers that can be given sequentially
(Fitzgerald et al., 2003; Pinto et al., 2003, 2004; Reyes-
Sandoval et al., 2004; Roy et al., 2004; Xiang et al., 2002,
2003a, 2003b, 2003c). The toxicity of adenoviral vectors in
vivo is directly related to the dose of injection. Therefore, a
major benefit of prime/boost strategy is the potential to
significantly reduce the dose for immunization in order to
achieve a high level of immune responses. In this study, we
showed that both AdHu5.CMVnSpike and AdC7.CAG2nS-
pike vaccine vectors could induce robust spike-specific CD8
T-cell responses in immunized mice alone. Currently, we are
studying whether strong CD8 T-cell responses can be
achieved when mice were primed and boosted with these
heterologous adenoviral vaccine vectors at a much lower
dose.Materials and methods
Construction of molecular clones of replication-defective
adenoviruses and production of vaccine vectors
Complementary DNA (cDNA) of spike gene for SARS-
CoV was isolated by RT-PCR from the viral RNA of the
SARS-CoV (Tor2 isolate). The PCR fragment was topo-
cloned (Invitrogen, CA) and characterized by sequencing at
SeqWright (SeqWright, TX), and was found to be 100%
identical to the published sequence (Marra et al., 2003).
Subsequently, Tor2 spike protein sequence was used as a
template to design a synthetic spike gene sequence with
human pattern of codon usage, according to Entelechon
Backtranslation software tool. Finally, cloned Tor2 spike
cDNA was used as a template and amplified with over-
lapping oligonucleotides in which human codon usage was
introduced. Resulting overlapping PCR fragments were
fused and full-length codon-optimized spike cDNA
(nSpike) was created.
To generate the molecular clones of AdHu5 vectors,
wild-type or codon-optimized spike insert was cloned into a
pShuttle plasmid, followed by homologous recombination
in bacterial cells using pAdEASY system (Invitrogen, CA).
Molecular clones of all AdC7 vectors used in the study were
created through a direct cloning and green-white selection
Y. Zhi et al. / Virology 335 (2005) 34–45 43procedure as described elsewhere (Gao et al., 2003b; Roy et
al., 2004). All of these molecular clones of replication-
defective AdHu5 and AdC7 vectors were transfected into
293 cells for virus rescue. The rescued vectors were
expanded to large-scale infections in 293 cells and purified
by the standard CsCl gradient sedimentation method.
Genome structures of the vectors were confirmed by
restriction analysis. Infectivity of the vectors was deter-
mined by the standard plaque assay on 293 cells and levels
of replication competent adenovirus (RCA) contaminants in
the vector preparations were inspected as described
previously (Gao et al., 2000).
Cells
293 and 293T cells were maintained in DMEM (Gibco-
Life Technologies, Grand Island, NY) supplemented with
antibiotic and 10% FBS (Hyclone, Logan, UT).
Mice
C57BL/6 and BALB/c mice (6–8 weeks old) were
purchased from Charles River Laboratories (Wilmington,
MA) and kept at the Animal Facility of The Wistar Institute
(Philadelphia, PA).
Peptides
Peptide library derived from the SARS-CoV spike protein
sequence was synthesized as 15 mers with 10-amino-acid
overlap with the preceding peptide (Mimotopes, Victoria,
Australia) and dissolved in DMSO at approximately 100 mg/
ml. Pools of 10 consecutive peptides were made and stored at
20 -C. Peptides were used at the concentration of 5 Ag/ml
in all experiments except the dose response studies and
DMSO concentrations were kept below 0.1% (v/v) in all
final assay mixtures.
Immunization of mice
Groups of three to five mice were immunized with
recombinant adenoviral vectors diluted in 100 Al phosphate-
buffered saline (PBS) given im.
Expression of spike from infected 293T cells and Western
blot analysis
293T cells were infected at 1000 particles/cell with each
recombinant adenoviral vector encoding spike protein.
Twenty-four hours later, cells were harvested and resus-
pended in lysis buffer and frozen at 20 -C. All samples
were normalized to the lysate with the lowest total protein
concentration by diluting with 4 SDS sample buffer
(Invitrogen, Carlsbad, CA) plus 5% h-mercaptoethanol.
The total protein content for all lysates was determined
using the Bradford assay (BioRad, Melville, NY). Dilutedsamples were heated to 94 -C for 4 min and loaded onto an
SDS–polyacrylamide gel. After electrophoresis, proteins
were transferred onto PVDF membrane. Blots were blocked
with 8% milk diluted in TBS/Tween 20 (TBS/T) for 45 min,
washed three times (10 min each) with TBS/T, and probed
with primary antibody at room temperature for 1 h. Primary
antibody consisted of whole serum isolated from rabbits
inoculated with purified spike protein diluted in 5% milk/
TBS to a final concentration of 1:500. The blots were then
washed three times with TBS/T before being incubated with
secondary antibody for 45 min at room temperature and
washed again three times with TBS/T. Secondary antibody
was anti-rabbit HRP diluted in 5% milk/TBS to a final
concentration of 1:2000 (Santa Cruz Biotechnology, Santa
Cruz, CA). Protein Bands were developed using Super-
Signal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL) and exposed on Kodak Biomax film. The
Western blot image was scanned and the interested protein
bands were quantified by ImageQuant5.1 (Molecular
Dynamics).
IFN-c ELISPOT assay
Assay was performed using ELISPOT Mouse Set (BD
PharMingen, San Diego, CA) following the protocol
provided by the vendor. Briefly, 96-well ELISPOT plate
was coated with 5.0 Ag/ml anti-mouse IFN-g capture
antibody overnight at 4 -C. Next day, wells were washed
and blocked with complete culture medium for 2 h at room
temperature. Splenocytes from immunized mouse were
added to microwells along with spike-specific peptides.
Cells were incubated at 37 -C and 5% CO2 for 18–20 h.
Control cells were incubated either without peptide or with
nonspecific stimulator, SEB (200 ng/ml). Then wells were
extensively washed with PBS containing 0.05% Tween 20
and subsequently incubated with 2.0 Ag/ml biotinylated
anti-mouse IFN-g detection antibody for 2 h at room
temperature. After washing, wells were incubated with 5 Ag/
ml Streptavidin-horseradish peroxidase antibody for 1 h at
room temperature. Wells were washed again, and final
substrate was added to wells. Color development was
monitored and stopped by washing with water. After drying
overnight at room temperature, wells were counted using an
ELISPOT reader.
Intracellular IFN-c staining
Splenocytes from immunized mice were stimulated with
spike-specific peptides for 5 h at 37 -C and 10% CO2 in the
presence of 1 Al/ml Brefeldin A (GolgiPlug, BD PharMin-
gen, San Diego, CA). Control cells were incubated without
peptide. After washing, cells were stained with either a
FITC-labeled anti-mouse CD8 antibody (BD PharMingen)
or a FITC-labeled anti-mouse CD4 antibody (BD PharMin-
gen). Then, cells were washed and permeabilized in Cytofix/
Cytoperm (BD PharMingen) for 20 min on ice. Subse-
Y. Zhi et al. / Virology 335 (2005) 34–4544quently, cells were washed again and stained with a PE-
labeled anti-mouse IFN-g antibody (BD PharMingen). After
extensively washing, cells were examined by two-color flow
cytometry and data were analyzed by WinMDi software.Acknowledgments
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